Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axalta Coating Systems Ltd.AXTA · Entity 3667 | SVP & CHRO | August 09, 2023 | August 11, 2023 |
| FMC CORPFMC · Entity 4704 | Executive VP & Chief HRO | September 28, 2026 | September 30, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | SVP, Global Human Resources | June 07, 2021 | June 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axalta Coating Systems Ltd.
Report date August 09, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 4,001 |
Reported balance
After 2023-08-09 transaction · row 1
1 source rowRow 1 · 2023-08-09 · Sale · Disposed 17,008 · Balance 4,001 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
FMC CORP
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,558 |
Reported balance
After 2026-09-28 transaction · row 1
1 source rowRow 1 · 2026-09-28 · Tax withholding · Disposed 5,137 · Balance 63,558 |
HAEMONETICS CORP
Report date June 07, 2021 · Filed June 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,216 |
Reported balance
After 2021-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-07 · Sale · Disposed 195 · Balance 4,216 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This number includes unvested RSUs previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This number includes unvested RSUs previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 19, 2020 21:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 110 | $100.44 | $11,048.40 |
DisclosureSEC source: 0001127602-20-017266 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,466 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs and 193 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2020. Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 207 | $99.63 | $20,623.41 |
DisclosureSEC source: 0001127602-20-010127 · form4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,383 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported and 13 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2019. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 118 | $98.00 | $11,564.00 |
DisclosureSEC source: 0001127602-20-010127 · form4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,590 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported and 13 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2019. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,299 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-20-010127 · form4.xml · derivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,299 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,299 | $100.50 | $130,549.50 |
DisclosureSEC source: 0001127602-20-010127 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,708 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported and 13 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2019. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,299 | $38.43 | $49,920.57 |
DisclosureSEC source: 0001127602-20-010127 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported and 13 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2019. Read SEC document |
| October 09, 2019 Filed Oct 10, 2019 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,379 | $124.61 | $171,837.19 |
DisclosureSEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,695 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.87, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 09, 2019 Filed Oct 10, 2019 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,230 | $123.57 | $151,991.10 |
DisclosureSEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,074 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.23 to $124.22, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 09, 2019 Filed Oct 10, 2019 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $122.37 | $36,711.00 |
DisclosureSEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,304 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.01 to $122.75, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 08, 2019 Filed Oct 10, 2019 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,295 | $122.34 | $280,770.30 |
DisclosureSEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 04, 2019 Filed Oct 8, 2019 20:37 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 5,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030271 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,899 F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on March 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from October 1, 2016 to September 30, 2019, as certified by the Compensation Committee of the Board of Directors on October 4, 2019. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,308 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-19-028195 · form4.xml · derivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,925 Underlying: Common Stock · 1,308 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,531 | $127.44 | $195,110.64 |
DisclosureSEC source: 0001127602-19-028195 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,695 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,308 | $93.52 | $122,324.16 |
DisclosureSEC source: 0001127602-19-028195 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,890 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0000899243-19-017286 · doc4.xml · derivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,779 Underlying: Common Stock · 2,890 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 259 | $112.49 | $29,134.91 |
DisclosureSEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,918 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 497 | $112.49 | $55,907.53 |
DisclosureSEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,177 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,890 | $112.49 | $325,096.10 |
DisclosureSEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,674 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,890 | $41.64 | $120,339.60 |
DisclosureSEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 108 | $109.37 | $11,811.96 |
DisclosureSEC source: 0001127602-19-021562 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,674 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 208 | $103.38 | $21,503.04 |
DisclosureSEC source: 0001127602-19-021239 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,782 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,342 | $0.00 Strike: $98.03 | $0.00 |
DisclosureSEC source: 0001127602-19-018736 · form4.xml · derivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,342 Underlying: Common Stock · 5,342 shares Expires 2026-05-14 F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,299 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-19-018736 · form4.xml · derivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,599 Underlying: Common Stock · 1,299 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018736 · form4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,990 F3 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The restricted stock units vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each restricted stock unit represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F5 · balance_after: This number includes unvested restricted stock units previously reported and 223 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2019. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,508 | $100.00 | $150,800.00 |
DisclosureSEC source: 0001127602-19-018736 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,237 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,299 | $38.43 | $49,920.57 |
DisclosureSEC source: 0001127602-19-018736 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 21:15 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 116 | $83.57 | $9,694.12 |
DisclosureSEC source: 0001127602-19-010840 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,446 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 22:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,027 | $104.22 | $107,033.94 |
DisclosureSEC source: 0001127602-18-036310 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,562 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported and 38 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2018. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,889 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · derivative · entry 7 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,669 Underlying: Common Stock · 2,889 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,299 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · derivative · entry 6 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,898 Underlying: Common Stock · 1,299 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 702 | $112.19 | $78,757.38 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,551 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,889 | $112.19 | $324,116.91 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,889 | $41.64 | $120,297.96 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,299 | $112.19 | $145,734.81 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,299 | $38.43 | $49,920.57 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,233 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020839 · form4.xml · derivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,233 Underlying: Common Stock · 5,233 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020839 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:37 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 214 | $92.73 | $19,844.22 |
DisclosureSEC source: 0001127602-18-020486 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,783 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported and 473 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2018. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 22:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 114 | $72.23 | $8,234.22 |
DisclosureSEC source: 0001127602-18-010745 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,524 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes 516 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.